CanBas Co

CanBas Co Interest Expense

The Interest Expense of CanBas Co (4575.T) as of Oct 19, 2026 is 59.30 M JPY. In the previous year, Interest Expense was -5.00 M JPY — a change of -1,286.51% (higher).

Interest Expense

59.30 MJPY

YoY

-1,286.51%

Last updated:

Interest Expense of CanBas Co is 2024 59.30 M JPY. Interest Expense of CanBas Co was 2023 -5.00 M JPY. It decreases by -1,286.51% higher compared to the previous year.

The CanBas Co Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2016
-13.75 M JPY
Jan 1, 2017
6.07 M JPY
Jan 1, 2018
-2.35 M JPY
Jan 1, 2019
91,000.00 JPY
Jan 1, 2020
-5.78 M JPY
Jan 1, 2021
-4.15 M JPY
Jan 1, 2022
-5.00 M JPY
Jan 1, 2024
59.30 M JPY
The CanBas Co Interest Expense history
YEARInterest ExpenseYoY
59.30 MJPY-1,286.51%
-5.00 MJPY+20.55%
-4.15 MJPY-28.28%
-5.78 MJPY-6,452.75%
91,000.00JPY-103.87%
-2.35 MJPY-138.75%
6.07 MJPY-144.17%
-13.75 MJPY-188.34%
15.56 MJPY+344.69%
3.50 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CanBas Co Stock analysis

What does CanBas Co do? CanBas Co Ltd is a biotechnology company based in Numazu-shi, Japan, operating within the healthcare sector. The company has a small team of 12 employees and went public on September 17, 2009, with its ticker listed as 4575.T and ISIN JP3244570002. Its primary focus is on anticancer drug discovery research, which includes developing drug discovery concepts, selecting candidate compounds through method-based approaches, conducting simple animal studies, and analyzing basic data on anticancer drug candidates entering development. Additionally, CanBas engages in early clinical development activities, such as preclinical studies required before submitting applications for clinical trials and conducting the initial phases of clinical trials. The company maintains a website at https://www.canbas.co.jp/ for further information. CanBas operates as a private entity with a minimal workforce, emphasizing research and development in the early stages of anticancer drug development. It does not provide details on specific products, acquisitions, or financial figures beyond its IPO date and employee count. The company's headquarters are located in Numazu-shi, Shizuoka Prefecture, Japan, and it is listed on the Tokyo Stock Exchange. Its operations are centered around foundational research in oncology, aiming to contribute to the discovery and development of new anticancer treatments. CanBas Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CanBas Co stock

Interest Expense of CanBas Co is 59.30 M JPY in 2024.

Interest Expense of CanBas Co changed from -5.00 M JPY to 59.30 M JPY, representing a -1,286.51% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense CanBas Co since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's CanBas Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — CanBas Co

All Key Metrics — CanBas Co